Literature DB >> 19763438

Activated epidermal growth factor receptor in ovarian cancer.

Laurie G Hudson1, Reema Zeineldin, Melina Silberberg, M Sharon Stack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19763438      PMCID： PMC3701255          DOI： 10.1007/978-0-387-98094-2_10

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  186 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

Review 2.  Normal ovarian surface epithelium.

Authors:  Alice S T Wong; Nelly Auersperg
Journal:  Cancer Treat Res       Date:  2002

Review 3.  EGF/ErbB receptor family in ovarian cancer.

Authors:  N J Maihle; A T Baron; B A Barrette; C H Boardman; T A Christensen; E M Cora; J M Faupel-Badger; T Greenwood; S C Juneja; J M Lafky; H Lee; J L Reiter; K C Podratz
Journal:  Cancer Treat Res       Date:  2002

4.  The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.

Authors:  I Skirnisdóttir; B Sorbe; T Seidal
Journal:  Int J Gynecol Cancer       Date:  2001 Mar-Apr       Impact factor: 3.437

5.  Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor.

Authors:  Z Chen; A Fadiel; Y Feng; K Ohtani; T Rutherford; F Naftolin
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

6.  Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.

Authors:  L Rosanò; M Varmi; D Salani; V Di Castro; F Spinella; P G Natali; A Bagnato
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

7.  Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.

Authors:  D A Fishman; Y Liu; S M Ellerbroek; M S Stack
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

8.  Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.

Authors:  K Sundfeldt; K Ivarsson; K Rask; M Haeger; L Hedin; M Brännström
Journal:  Anticancer Res       Date:  2001 Jan-Feb       Impact factor: 2.480

9.  Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.

Authors:  E S Bergmann-Leitner; T A Bennett; N F Hacker; K Stromberg; W G Stetler-Stevenson
Journal:  J Natl Cancer Inst       Date:  2001-09-19       Impact factor: 13.506

10.  Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype.

Authors:  Lars Damstrup; Mikkel Wandahl Pedersen; Lone Bastholm; Folmer Elling; Hans Skovgaard Poulsen
Journal:  Int J Cancer       Date:  2002-01-01       Impact factor: 7.396
View more
  16 in total

1.  Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Authors:  Imran Rizvi; Tri A Dinh; Weiping Yu; Yuchiao Chang; Margaret E Sherwood; Tayyaba Hasan
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

Review 2.  EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.

Authors:  Laurie G Hudson; Natalie M Moss; M Sharon Stack
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

3.  Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen.

Authors:  Natalie M Moss; Yueying Liu; Jeff J Johnson; Philip Debiase; Jonathan Jones; Laurie G Hudson; Hidayatullah G Munshi; M Sharon Stack
Journal:  Mol Cancer Res       Date:  2009-06-09       Impact factor: 5.852

Review 4.  StarD13 negatively regulates invadopodia formation and invasion in high-grade serous (HGS) ovarian adenocarcinoma cells by inhibiting Cdc42.

Authors:  Sandra Abdellatef; Isabelle Fakhoury; Maria Al Haddad; Leila Jaafar; Hiba Maalouf; Samer Hanna; Bassem Khalil; Zeinab El Masri; Louis Hodgson; Mirvat El-Sibai
Journal:  Eur J Cell Biol       Date:  2021-12-21       Impact factor: 4.492

Review 5.  Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.

Authors:  Maria V Barbolina; Rebecca J Burkhalter; M Sharon Stack
Journal:  Biochem J       Date:  2011-07-01       Impact factor: 3.857

6.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

Review 7.  Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.

Authors:  Vera Loizzi; Vittoria Del Vecchio; Giulio Gargano; Maria De Liso; Anila Kardashi; Emanuele Naglieri; Leonardo Resta; Ettore Cicinelli; Gennaro Cormio
Journal:  Int J Mol Sci       Date:  2017-09-14       Impact factor: 5.923

8.  Targeting the EGF receptor for ovarian cancer therapy.

Authors:  Reema Zeineldin; Carolyn Y Muller; M Sharon Stack; Laurie G Hudson
Journal:  J Oncol       Date:  2009-12-28       Impact factor: 4.375

Review 9.  Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.

Authors:  Shuvolina Mukherjee; Karin Sundfeldt; Carl A K Borrebaeck; Magnus E Jakobsson
Journal:  Proteomes       Date:  2021-05-25

Review 10.  Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Authors:  Heather J Bax; Debra H Josephs; Giulia Pellizzari; James F Spicer; Ana Montes; Sophia N Karagiannis
Journal:  MAbs       Date:  2016-08-05       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.